Citizens Jmp Cuts Savara (NASDAQ:SVRA) Price Target to $10.00

Savara (NASDAQ:SVRA) had its target price lowered by Citizens Jmp from $11.00 to $10.00 in a research note issued on Thursday,Benzinga reports. The brokerage currently has a “market outperform” rating on the stock. Citizens Jmp’s price objective points to a potential upside of 138.44% from the stock’s current price.

SVRA has been the topic of a number of other reports. Lifesci Capital upgraded shares of Savara to a “strong-buy” rating in a research report on Tuesday, October 14th. Wells Fargo & Company initiated coverage on shares of Savara in a research note on Monday, October 20th. They issued an “overweight” rating and a $7.00 target price for the company. JMP Securities increased their price target on Savara from $8.00 to $11.00 and gave the stock a “market outperform” rating in a report on Thursday, October 23rd. Citigroup reiterated an “outperform” rating on shares of Savara in a report on Thursday, October 23rd. Finally, HC Wainwright increased their price objective on shares of Savara from $5.00 to $8.00 and gave the stock a “buy” rating in a research report on Wednesday, September 3rd. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $8.14.

Savara Price Performance

Shares of NASDAQ SVRA traded up $0.07 during midday trading on Thursday, reaching $4.19. 2,504,660 shares of the company traded hands, compared to its average volume of 1,322,693. Savara has a 12 month low of $1.89 and a 12 month high of $4.51. The company has a debt-to-equity ratio of 0.25, a quick ratio of 11.08 and a current ratio of 11.08. The stock’s 50-day simple moving average is $3.78 and its 200-day simple moving average is $3.05. The firm has a market cap of $724.88 million, a PE ratio of -8.39 and a beta of 0.45.

Savara (NASDAQ:SVRA) last announced its earnings results on Wednesday, November 12th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01). As a group, equities analysts anticipate that Savara will post -0.45 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Savara

A number of large investors have recently made changes to their positions in the company. Prudential Financial Inc. bought a new stake in Savara in the 2nd quarter valued at about $30,000. BNP Paribas Financial Markets raised its position in shares of Savara by 52.3% in the second quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company’s stock valued at $31,000 after buying an additional 4,626 shares in the last quarter. May Hill Capital LLC bought a new stake in shares of Savara in the second quarter valued at approximately $32,000. Brevan Howard Capital Management LP acquired a new stake in Savara during the second quarter worth approximately $33,000. Finally, Russell Investments Group Ltd. increased its stake in Savara by 930.5% during the 3rd quarter. Russell Investments Group Ltd. now owns 10,480 shares of the company’s stock worth $37,000 after acquiring an additional 9,463 shares during the period. Institutional investors own 87.93% of the company’s stock.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.